Medis
Luka Podboršek is a medical representative at Medis since August 2024. Notably, Luka contributed to the synthesis of Butyrylcholinesterase enzyme degraders for a Master's thesis at the University of Ljubljana's Faculty of Pharmacy from February 2023 to September 2024, under the mentorship of an assistant professor. Luka held a representative role for international collaboration in the Student's Organisation Faculty of Pharmacy at DŠFS from October 2021 to September 2024 and served as Head Erasmus Tutor Coordinator for exchange students during an internship at Lekarna Ljubljana from March 2024 to July 2024. Previous experience includes a market access and marketing internship at Medis from July 2023 to February 2024, and participation in the Helping Team for the 44th EPSA Annual Congress in 2023. Luka is pursuing a Master’s degree in Pharmacy at the University of Ljubljana, building upon a solid foundation from Gimnazija Vič, where studies were completed from 2014 to 2018.
This person is not in any offices
Medis
1 followers
For 34 years, we have been collaborating with global pharma and biotech partners to bring innovative therapies to patients in Central and Eastern Europe. Despite the region's challenging healthcare systems and complex yet promising markets, our team of 400 employees harnesses its expertise to ensure health equity in these underserved markets. Medis is a member of the World Orphan Drug Alliance (WODA) – a global alliance of full-service regional distributors for orphan and debilitating disease products. WODA covers 152 countries in the following regions: Central and Eastern Europe, Greater China, Israel, Greece, Malta, Cyprus, Latin America, the Middle East, North Africa & Turkey, Switzerland, Australia, New Zealand and South East Asia. Out-licensing: Become our commercialization partner and benefit from advanced, ready-to-launch consumer health products, which are already marketed in 20 countries and are further expanding. More information: www.medis.com/en/international-business/ Our business areas: • Therapeutics • Hospital Care • Consumer Health • Aesthetics Our value to partners: • Direct local presence in 18 CEE countries • Full commercialization • Single point of contact and delivery • Strategic and localized market access approach • Highest compliance standards • Financial and credit excellence Major Partners: • Therapeutics: Bial – Biogen – Besins – HRA Pharma – Mundipharma – Pierre Fabre – Santen – UCB • Hospital Care: Abbott – Aesculap – Asahi Medical – Biotest – B. Braun – Cytosorbents – Paion • Consumer Health: Pleuran – Ricerpharma – Karo Healthcare – Merz – Pohl Boskamp – UP – URGO • Aesthetics: Merz Aesthetics – Crown Aesthetics • Out-licensing partners: Ferrer – Pharmalink – Sarantis – Stada